Recombinant Rat AGER/RAGE protein (His Tag)

Species

Rat

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg1135

---

Validation Data Gallery

• 

  Purity of Recombinant Rat AGER was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Rat AGER protein Gly23-Leu341 (Accession# Q63495) with a His tag at the C-terminus.
• GeneID: 81722
• Accession: Q63495
• PredictedSize: 34.9 kDa
• SDS-PAGE: 40-45 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Advanced glycosylation end product-specific receptor (AGER, also known as RAGE) is a member of the immunoglobulin superfamily of cell surface receptors, which interacts with distinct families of ligands, mediating diverse functions in a broad array of cell types including cellular migration, proliferation, survival and apoptosis. It senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, phospholipids and glycosaminoglycans. It interacts with distinct molecules implicated in homeostasis, development, inflammation, and certain diseases such as diabetes and Alzheimer's disease.

References:

1.Donato, R. et al. (2003) MICROSC RES TECHNIQ. 60(6):540-51.
2.Yan, SF.et al. (2007) CURR DIABETES REP. 7(2):146-53.
3.Tsoporis, JN. et al. (2010) CIRC RES. 106(1):93-101.
4.Xie, Y. et al. (2017) MOL MED REP. 16(2):1691-1700.
5.Daffu, G. et al. (2015) DIABETES. 64(12):4046-60.